• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Neo-adjuvant radiation and intratumoral immunotherapy followed by surgery- trial for extremity soft tissue sarcoma.新辅助放疗和肿瘤内免疫治疗联合手术治疗肢体软组织肉瘤的临床试验。
Future Oncol. 2024;20(30):2233-2240. doi: 10.1080/14796694.2024.2385291. Epub 2024 Sep 13.
2
Functional and Oncological Outcomes in Patients With Surgically Treated Lower Extremity Soft Tissue Sarcoma.接受手术治疗的下肢软组织肉瘤患者的功能和肿瘤学结局
Cancer Control. 2025 Jan-Dec;32:10732748251374416. doi: 10.1177/10732748251374416. Epub 2025 Aug 28.
3
Efficacy and safety of NeoAdjuvant chemotherapy with or without tIslelizumab followed by debulking surgery for oVarian cancEr (NAIVE study) in China: study protocol of an open-label, phase II, randomised controlled trial.中国新辅助化疗联合或不联合替雷利珠单抗随后进行减瘤手术治疗卵巢癌（NAIVE研究）的疗效和安全性：一项开放标签、II期、随机对照试验的研究方案
BMJ Open. 2025 Feb 5;15(2):e092545. doi: 10.1136/bmjopen-2024-092545.
4
A systematic overview of radiation therapy effects in soft tissue sarcomas.软组织肉瘤放射治疗效果的系统综述。
Acta Oncol. 2003;42(5-6):516-31. doi: 10.1080/02841860310014732.
5
Study protocol: randomized phase III trial of neo-adjuvant and adjuvant chemotherapy vs. immediate surgery and adjuvant chemotherapy for localized soft tissue sarcoma: Japan Clinical Oncology Group study JCOG2102 (NACLESS).研究方案：局部软组织肉瘤新辅助化疗和辅助化疗对比直接手术及辅助化疗的随机III期试验：日本临床肿瘤学会研究JCOG2102（NACLESS）
Jpn J Clin Oncol. 2025 Mar 5;55(3):297-303. doi: 10.1093/jjco/hyae160.
6
Low rate of function-limiting side effects with high-dose adjuvant radiotherapy in high-grade soft tissue extremity sarcomas: a retrospective single-center analysis over 10 years.大剂量辅助放疗在高级别肢体软组织肉瘤中具有较低的功能受限副作用发生率：一项回顾性单中心分析超过 10 年。
J Cancer Res Clin Oncol. 2023 Jul;149(8):4877-4888. doi: 10.1007/s00432-022-04423-1. Epub 2022 Oct 26.
7
Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer.对局部晚期宫颈癌女性患者进行子宫切除术并辅以放疗或化疗或两者联合治疗。
Cochrane Database Syst Rev. 2015 Apr 7(4):CD010260. doi: 10.1002/14651858.CD010260.pub2.
8
Selective neoadjuvant therapy of rectal cancer patients (SELREC): study protocol for a European randomised controlled, open, multicentre non-inferiority trial.直肠癌患者的选择性新辅助治疗（SELREC）：一项欧洲随机对照、开放、多中心非劣效性试验的研究方案
BMJ Open. 2025 Jun 26;15(6):e092807. doi: 10.1136/bmjopen-2024-092807.
9
A phase II randomized trial of individualized neoantigen peptide vaccine combined with unusual radiotherapy (iNATURE) in advanced solid tumors-GCOG0028.一项关于个体化新抗原肽疫苗联合非常规放疗（iNATURE）用于晚期实体瘤的II期随机试验——GCOG0028
Front Immunol. 2025 Aug 21;16:1538032. doi: 10.3389/fimmu.2025.1538032. eCollection 2025.
10
Interventions for necrotizing soft tissue infections in adults.成人坏死性软组织感染的干预措施。
Cochrane Database Syst Rev. 2018 May 31;5(5):CD011680. doi: 10.1002/14651858.CD011680.pub2.

本文引用的文献

1
Gut microbiota-mediated nucleotide synthesis attenuates the response to neoadjuvant chemoradiotherapy in rectal cancer.肠道微生物群介导的核苷酸合成减弱了直肠癌对新辅助放化疗的反应。
Cancer Cell. 2023 Jan 9;41(1):124-138.e6. doi: 10.1016/j.ccell.2022.11.013. Epub 2022 Dec 22.
2
Hypofractionated, 3-week, preoperative radiotherapy for patients with soft tissue sarcomas (HYPORT-STS): a single-centre, open-label, single-arm, phase 2 trial.软组织肉瘤患者的短程、3 周术前放疗（HYPORT-STS）：一项单中心、开放标签、单臂、Ⅱ期临床试验。
Lancet Oncol. 2022 Dec;23(12):1547-1557. doi: 10.1016/S1470-2045(22)00638-6. Epub 2022 Nov 4.
3
Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.软组织肉瘤，第 2.2022 版，NCCN 肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2022 Jul;20(7):815-833. doi: 10.6004/jnccn.2022.0035.
4
Commensal bacteria and fungi differentially regulate tumor responses to radiation therapy.共生细菌和真菌可差异化调节肿瘤对放射疗法的反应。
Cancer Cell. 2021 Sep 13;39(9):1202-1213.e6. doi: 10.1016/j.ccell.2021.07.002. Epub 2021 Jul 29.
5
Radiation Therapy for Treatment of Soft Tissue Sarcoma in Adults: Executive Summary of an ASTRO Clinical Practice Guideline.成人软组织肉瘤放射治疗：ASTRO 临床实践指南执行摘要。
Pract Radiat Oncol. 2021 Sep-Oct;11(5):339-351. doi: 10.1016/j.prro.2021.04.005. Epub 2021 Jul 26.
6
Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies.检查点抑制剂的免疫相关毒性：机制与缓解策略。
Nat Rev Drug Discov. 2022 Jul;21(7):495-508. doi: 10.1038/s41573-021-00259-5. Epub 2021 Jul 27.
7
Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up.软组织和内脏肉瘤：ESMO-EURACAN-GENTURIS诊断、治疗及随访临床实践指南
Ann Oncol. 2021 Nov;32(11):1348-1365. doi: 10.1016/j.annonc.2021.07.006. Epub 2021 Jul 22.
8
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade.肠道微生物组特征与 CTLA-4 和 PD-1 联合阻断的毒性相关。
Nat Med. 2021 Aug;27(8):1432-1441. doi: 10.1038/s41591-021-01406-6. Epub 2021 Jul 8.
9
Efficacy and Safety of Hypofractionated Preoperative Radiotherapy for Primary Locally Advanced Soft Tissue Sarcomas of Limbs or Trunk Wall.肢体或躯干壁原发性局部晚期软组织肉瘤术前短程放疗的疗效与安全性
Cancers (Basel). 2021 Jun 14;13(12):2981. doi: 10.3390/cancers13122981.
10
Radiation-induced neoantigens broaden the immunotherapeutic window of cancers with low mutational loads.辐射诱导的新生抗原拓宽了低突变负荷癌症的免疫治疗窗口。
Proc Natl Acad Sci U S A. 2021 Jun 15;118(24). doi: 10.1073/pnas.2102611118.

新辅助放疗和肿瘤内免疫治疗联合手术治疗肢体软组织肉瘤的临床试验。

Neo-adjuvant radiation and intratumoral immunotherapy followed by surgery- trial for extremity soft tissue sarcoma.

机构信息

The Comprehensive Cancer Center of Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.

Department of Orthopaedics, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.

出版信息

Future Oncol. 2024;20(30):2233-2240. doi: 10.1080/14796694.2024.2385291. Epub 2024 Sep 13.

DOI:10.1080/14796694.2024.2385291
PMID:39268916
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11508951/
Abstract

Extremity soft tissue sarcoma (ESTS) is a rare malignant nonepithelial disease, calling for combined modality treatments with surgery to further improve local control rates and long-term survival, especially in patients with multiple local recurrences with or without risk of amputation. In this double-arm, open-label, Phase II clinical trial, we will enroll 30 patients with pathologically confirmed ESTS without nodal involvement or distant metastases. Patients are randomly assigned to the combination treatment group or the radiation monotherapy group. Additionally, tumor and biological samples will be obtained directly before and after neoadjuvant therapy, allowing for studies of immune response and primary drug resistance mechanisms. ChiCTR2200060659 (http://www.chictr.org.cn) (ClinicalTrials.gov).

摘要

肢体软组织肉瘤（ESTS）是一种罕见的恶性非上皮性疾病，需要采用联合治疗模式，包括手术，以进一步提高局部控制率和长期生存率，尤其是对于那些存在多次局部复发且有或无截肢风险的患者。在这项双臂、开放标签、II 期临床试验中，我们将招募 30 名经病理证实且无淋巴结受累或远处转移的 ESTS 患者。患者将被随机分配至联合治疗组或单纯放疗组。此外，将在新辅助治疗前后直接获取肿瘤和生物样本，以进行免疫反应和原发性药物耐药机制的研究。ChiCTR2200060659（http://www.chictr.org.cn）（ClinicalTrials.gov）。